First patient in Tetraphase’s IGNITE4 study dosed

Tetraphase Pharmceuticals has placed its first patient in its Phase 3 IGNITE4 clinical study involving intravenous eravacycline has been dosed with the medication.
The IGNITE4 study was designed to assess the safety and effectiveness of IV eravacycline in comparison with meropenem in complicated intra-abdominal infections (cIAI).
“Patient dosing is now underway in IGNITE4, and we continue to expect top-line data in the fourth quarter of 2017. If successful, these data, along with data from our positive IGNITE1 study in cIAI, will support a new drug application (NDA) submission for IV eravacycline in cIAI,” Tetraphase President and CEO Guy Macdonald said. “Antibiotic resistance continues to be a growing public health threat and this critical issue is achieving attention on a global scale, most recently as an area of focus at the United Nations General Assembly. Tetraphase is committed to being part of the solution by working to develop new antibiotics to treat these serious infections.”
Eravacycline is a novel antibiotic candidate that strongly counteracts pathogens that are multi-drug resistant. This includes carbapenemresistantenterobacteriaceae, Acinetobacter baumannii and colistin-resistant bacteria that transport the mcr-1 gene. Eravacycline was designed to treat bacterial infections that are serious and life-threatening.